Regulations.gov document
Ref. 39 - Considerations for the Design of Early-Phase Clinical Trials of Cellular and…
Supporting & Related Material · FDA-2021-D-0404 · posted Mar 18, 2022
Key facts
| Document ID | FDA-2021-D-0404-0039 |
|---|---|
| Title | Ref. 39 - Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene 1476 Therapy Products: Guidance for Industry, June 2017,Re: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Draft Guidance for Industry |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2021-D-0404 |
| Posted | Mar 18, 2022 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: